Van Berlo et al, 2013)
Trejo JI, Piriz J, Llorens-Martin MV et al (2007) Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects
In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets
No fluid retention, no anemia, no renal impairment
Additionally, many patients find that the once-daily regimen fits seamlessly into their routines, allowing them to focus on their daily activities without the distraction of needing to remember multiple doses
Lactis and inflammation, curcumin and inflammatory markers